Medication Assisted Treatment for the 21st Century: Community Education Kit.

Substance Abuse and Mental Health Services Administration (DHHS/PHS), Rockville, MD. Center for Substance Abuse Treatment.

2003-00-00

32p.

National Clearinghouse for Alcohol and Drug Information, P.O. Box 2345, Rockville, MD 20847-2345. Tel: 301-468-2600; Tel: 800-729-6686 (Toll Free); Tel: 800-487-4089 (TDD). For full text: http://www.samhsa.gov.

Guides - Non-Classroom (055)

EDRS Price MF01/PC02 Plus Postage.

Counseling Techniques; *Delivery Systems; *Drug Addiction; *Drug Rehabilitation; Outcomes of Treatment; Pharmacology; *Program Development; *Program Effectiveness; Substance Abuse

The need to support the success of individuals in methadone-assisted recovery, and the recent availability of new pharmacologic treatment options for opioid dependence, calls for an information tool that underscores the evidence-based benefits of medication assisted treatment for opioid dependence. The U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration (SAMHSA), produced this education kit in collaboration with a host of opioid dependence treatment professional, service providers, and individuals in recovery from opioid dependence. This tool addresses key questions related to new and existing opioid dependency medications and the new roles for opioid dependence service delivery systems. The materials included here can be used by local alcohol and drug treatment providers to broaden the knowledge base about methadone and other medication-related options for the treatment of opioid dependence. This education kit also includes information on how to best approach and sustain an ongoing dialogue with key community stakeholders about the establishment, expansion, or sustainability of community-based treatment programs that use medication-supported treatment options. Most importantly, this kit contains key suggestions as to how to develop a coordinated community education effort aimed at reducing the stigma associated with opioid dependence and its service delivery systems. (Author)
Medication Assisted Treatment for the 21st Century

Community Education Kit

U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Treatment
www.samhsa.gov
Introduction: Usefulness of This Community Education Kit

Anybody can be addicted to opiates...
College students, fashion models, stockbrokers...
Your next door neighbor...
Your own child...

The need to support the success of individuals in methadone-assisted recovery, and the recent availability of new pharmacologic treatment options for opioid dependence, calls for an information tool that underscores the evidence-based benefits of medication-assisted treatment for opioid dependence.

The U.S. Department of Health and Human Services' Substance Abuse and Mental Health Services Administration (SAMHSA), produced this education kit in collaboration with a host of opioid dependence treatment professionals, service providers, and individuals in recovery from opioid dependence. This tool addresses key questions related to new and existing opioid dependency medications and the new roles for opioid dependence service delivery systems.

The materials included here can be used by local alcohol and drug treatment providers to broaden the knowledge base about methadone and other medication-related options for the treatment of opioid dependence. This education kit also includes information on how to best approach and sustain an ongoing dialogue with key community stakeholders about the establishment, expansion, or sustainability of community-based treatment programs that use medication-supported treatment options.

Most importantly, this kit contains key suggestions as to how to develop a coordinated community education effort aimed at reducing the stigma associated with opioid dependence and its service delivery systems.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Treatment
www.samhsa.gov
SAMHSA's Center for Substance Abuse
Treatment Plan Initiative to Improve Substance Abuse Treatment, published in 2000, recognized that stigma surrounding drug use is an obstacle to treatment. Moreover, stigma associated with drug use and dependence supports a set of negative beliefs or attitudes that often impedes those who are in recovery from realizing their full potential and discourages those who are in need of treatment from seeking help. This education kit provides the knowledge necessary to dispel negative public attitudes, and points the way for supporting those in recovery. We hope that its message is well received in your community.

Disclaimer

The views and opinions expressed are those of the contributors and reviewers and do not necessarily reflect the official position of the Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS). The guidelines proffered in this document should not be considered as substitutes for individualized client care and treatment decisions.

Public Domain Notice

All material appearing in this education kit except that taken directly from copyrighted sources is in the public domain and may be reproduced or copied without permission from SAMHSA/CSAT or the authors.

Electronic Access and Copies of Publication

Do not reproduce or distribute this publication for a fee without specific, written authorization from SAMHSA's Office of Communications. Copies may be obtained free of charge from SAMHSA's National Clearinghouse for Alcohol and Drug Information (NCADI), (800) 729-6686 or (301) 468-2600; TDD (for hearing impaired), (800) 487-4889, or electronically through the following Internet World Wide Web site: www.samhsa.gov/centers/csatsat.html.

Acknowledgments

Numerous people contributed to the development of this education kit with the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS). The information contained in this education kit was compiled and edited by American Association for the Treatment of Opioid Dependence Public Relations Committee members and affiliates: Dorie Burke; William Gouldman; Susan Guercio; Herman Joseph, Ph.D.; Dan McGill; and Gerry Migliore.

In addition, special thanks to the following individuals for providing a field review of the materials. Reviewers include Jay Clarke, Virginia Association of Methadone Advocates; Thomas Davis, Maryland Drug and Alcohol Council; Eric Ennis, Addiction Research and Treatment Services, University of Colorado School of Medicine; Ron Jackson, M.S.W., Evergreen Treatment Services, Seattle, Washington; Herman Joseph, Ph.D., Senior Researcher, New York State Office of Alcoholism and Substance Abuse Services; Dan McGill, New York State Office of Alcoholism and Substance Abuse Services; Laura McNicholas, M.D., Ph.D., VA Medical Center, University of Pennsylvania; and Deb Rienheimer, Maryland State Methadone Authority.
Public Relations Inside Treatment Facilities

Good public relations begin at home. A public relations program engenders a sense of personal responsibility for successful treatment and helps counteract stigma.

Public Relations with Staff and Other Professionals

- **Create a Mission Statement:** Provide a clear sense of direction and purpose within the organization. Keep treatment patient-focused and keep clinicians and administrators on track in program development.

- **Develop Personal Relationships with Referral Agencies:** Be available and responsive to agencies that are new to working with patients in opioid pharmacotherapy treatments by providing support and in-service training.

Public Relations with Patients

Accreditation requires, and quality opioid pharmacotherapy treatment includes, a plan for input from patients to assure patient involvement in treatment planning and improvements in the practices and policies of the organization.

Medication assisted treatment programs need to foster a patient-based treatment environment in which patients understand and are fully part of the care they receive.

- **Create a Patient Committee to:**
  - Advise on policies and procedures.
  - Participate in public education projects and programs support initiatives.
  - Encourage civic involvement.
  - Involve recovery patients in the agency’s community and media relations to counteract stigma.

- **Empower Patients in Their Treatment:**
  - Conduct patient satisfaction surveys.
  - Introduce and encourage participation in medication assisted treatment advocacy groups.
  - Establish and support open self-help groups, such as a Methadone Anonymous and/or Narcotics Anonymous meetings.
  - Provide patient recognition ceremonies.
  - Provide updates as program rules and services change.
Public Relations with and for Families

A satisfied family member is your best spokesperson in support of medication assisted treatment.

- Educate family members about the program’s services and the principles of medication assisted treatment.

- Invite family members to be involved in education efforts to promote the benefits of medication assisted treatment.
Establishing Community Relations

Treating patients is treating communities, as well. Many opioid pharmacotherapy treatment programs do, and others can, enjoy a positive and naturally occurring relationship with their “community-at-large.”

Why Community Relations?

- **Patients Reflect Their Communities:** Patients mirror their communities’ needs for adequate health care, employment, economic viability, basic safety, housing, and education. Quality care for patients means promoting patient reintegration, acceptance, and success of patients. It means understanding community values, needs, and resources, and working collaboratively with community members and organizations.

- **Programs Affect Community Life:** Programs impact community health, education, and well-being, and are uniquely positioned to provide resources.

Proactive Community Relations Plans

Medication assisted treatment programs that have proactive community relations plans help place their programs in the mainstream of community services. Proactive plans establish ongoing relationships with community leaders and organizations to further the interests of patients and communities.

- **Set Community Relations Mission, Goals, and Protocols:**
  - Learn about community structures. Know who represents and leads the community in government, business, health, education, and other community systems. Identify ways that the program can partner with these groups to help meet community needs.
  - Designate program staff as community liaisons or coordinators.
  - Actively participate in your network of services.
  - Recruit and hire qualified personnel from the community.
  - Establish feedback mechanisms to hear, monitor, and effectively follow up community concerns about program impact. Address such issues as loitering near the clinic, and work closely with local law enforcement to address these and other community concerns.
  - Establish a community-based Board of Directors or Advisory Council.

*U.S. Department of Health and Human Services*
*Substance Abuse and Mental Health Services Administration*
*Center for Substance Abuse Treatment*
*www.samhsa.gov*

*Medication Assisted Treatment for the 21st Century*
• Collaborate with the Community to Identify Appropriate Sites for Treatment Facilities:
  
  • Acquire knowledge of all laws and regulations pertaining to new clinic siting, relocation, or expansion.
  
  • Consult with community leaders and planning agencies to identify potential program sites.
  
  • Provide an ongoing forum to discuss and address community concerns.
  
  • Assure quality physical plant design and a clean, professional external appearance.
  
  • Establish convenient program hours that do not impede community traffic.
  
  • Maintain a “barrier-free” facility that does not impede pedestrian or vehicular flow in the program vicinity.
  
• Open Dialogue with Community Leaders:
  
  • Contact and communicate with elected representatives, human services agencies, business organizations, local police and law enforcement, and the faith community.
  
  • Establish a community liaison or advisory group that meets to share and exchange information about the program and to discuss issues of mutual concern.
  
• Host community liaison events to allow community interaction with program staff and patients.
  
• Participate in community forums.

• Proactively Serve the Community-at-Large:
  
  • Promote accurate information about substance abuse and addiction treatment.
  
  • Develop a volunteer corps to assist with community development and enhancement activities.
  
  • Sponsor community events.
  
  • Form a speakers bureau.
  
  • Publish informational brochures and/or a newsletter.
  
  • Engage patients and staff in collaborative community improvement projects.
  
  • Serve on community health and social services boards.
  
  • Encourage staff and patients to join community organizations.
  
  • Conduct effective media relations. See “Media Relations and Outreach” in this kit.
Successful media relations and outreach enhance the image of an agency, contribute to the public’s understanding of the program’s mission and quality of care, and generate community support.

The Value of Media Relations

Outreach to the media can generate positive focus on a program’s mission and quality of care. Media exposure demystifies treatment, counteracts stigma, enhances program image, and improves the potential for a more balanced reaction when negative incidents or views threaten to undermine patients, the program, or treatment.

Adopting Media Strategies

An array of approaches may be incorporated into a treatment program’s media campaign.

• Identify Media Outlets and Publications:
  
  • Identify and get to know reporters, editors, and radio/television producers who have knowledge of, or report on, health, health care, social welfare, and/or treatment issues and developments.
  
  • Offer your expertise to reporters, editors, and radio and television stations as a credible source on treatment issues and developments.
  
  • Radio, particularly “all news” stations, is the most effective media for airing “breaking news” stories.
  
  • Utilize community newspapers and ethnic press.

• Pitch a Story: A good story about treatment and patients portrayed through the media can both educate and promote program support. Broadcasters are looking for unique and interesting stories.
  
  • The best stories tie the personal concerns of the public to the positive activities of the program.
  
  • Generate media interest and maximize potential for coverage through a pitch that reflects newsworthiness, emphasizes something people in the community would want to know and/or has relevance to current community events or concerns.

• Develop Fact Sheets - Useful Tools for Encounters with the Media: Provide media sources with figures and basic information that will be useful in preparing their stories.
  
  • Prepare program fact sheets of one or two pages of clearly presented program information including the mission, program description, including history and types of services offered, and data on patients served.
  
  • Interact with the local health department to get accurate data to prepare general fact sheets on health status trends, including addiction. Include brief descriptions or “bullets” on local addiction and health-related or social issues.
• Develop a program website and include the organization's history, mission, programs and services, outcomes, admission requirements, activities, hours of operation, and driving directions.

• **Write Letters to Newspaper Editors:** Bring attention to important treatment issues by responding to newspaper articles that may affect your program or patients.

  • Send letters to the editor within 48 hours of appearance of the original article to maximize probability of publication.

  • Make letters brief, succinct (250 words or less), and clearly tied to issues presented in the article.

• **Place Op-Ed Pieces:** Most newspapers publish opinion columns opposite their editorial page. The op-ed page is an excellent place to raise awareness of important issues about treatment and recovery.

  • Identify the news publications in the program's community that publish op-ed pages and learn about their publication policies and criteria.

  • Introduce the op-ed at a time when opioid dependence is a hot topic in the community, such as local special events or a conference in the community.

  • Submit the op-ed piece with a cover letter that identifies the author, affiliation, and description of the author's expertise. Include background information about the provider agency, a statement of the topic, and why the views are important.

• **Issue Press Releases:** Many news stories are triggered by a timely press release. Press releases provide the opportunity to publicize and promote knowledge about the program treatment modality, or specific activities. The best time to get news coverage of a public interest story is on the weekend, which is a “slower” news time, so time press releases accordingly. Examples of noteworthy press releases:

  • The introduction of new services, significant changes to existing services, or dedication of a new facility.

  • The appointment of a new director or high-level staff person.

  • Receipt of a grant or donation.

  • Promotion of the local impact of a national event.

  • Unique research findings or outcomes at the program, or a grant to conduct research.

  • Formation of a special task force.

  • Presentation of special seminars, fairs, conferences, or workshops open to community members, or featuring an expert lecturer or speaker of local or national prominence.

  • Plans for local activities and events to tie into celebration of a well-known day, week, or month.

  • Receipt or conferring of honors or awards to or by the organization, its staff, or its patients.

  • Details of a specific, unique program offered to patients or community.

  • Agency commitment to the community to identify available community-based services.

  • Human interest story about a particular patient's noteworthy treatment success or accomplishment.

  • Brief human-interest story of a unique, effective intervention between the provider and patients.
Press Release Tips

- Follow the standard format of press releases – no more than two pages, double-spaced, short sentences and paragraphs, reproduced on official organization letterhead, with name and phone number of a contact. Refer to the Sample Press Release in this kit for specific format specifications.

- Be sure the press release is professional and accurate. Answer the five questions – “who, what, where, when, and how?” Avoid using slang or technical terms, or explain them if necessary. Spelling, statistics, names, and titles should be accurate. Editorial comments or other opinions are expressed only in direct quotes.

- Use photographs or visuals to enhance or depict the information presented in the press release. Attach a caption to the photo. Use of patient’s photos, name, identity, or likeness requires prior written authorization from the individual.

- Distribute press releases to local print (including neighborhood weekly newspapers), radio, and television reporters in the community. Follow up to encourage them to write or air a story. Try to schedule an interview with an official or representative of the provider organization.

- Develop and Place Radio Public Service Announcements: Public Service Announcements (PSA) provide free air time if used to promote a nonprofit organization or public service. Stations often will accept pre-written scripts from organizations.

- Contact local radio stations to identify Public Affairs Directors and policies or options for submission of PSAs and underwriting opportunities.

- Script brief and to the point PSAs. Include a phone number that can be used to find out more about treatment services. Fax or mail copies of PSA scripts along with an agency contact name and telephone number. Sample 30-second and 15-second radio PSA scripts available for use are in this kit. See Sample PSAs.

- Use Press Clips, Fact Sheets, Press Releases, and Public Service Announcements to Build Constituencies: Collect and document published or transcripted media reports, fact sheets, press releases, PSAs, and other forms of media outreach such as interviews, and share them with program constituents. Distribute them to local community leaders, government, civic and elected officials, and colleagues to highlight your media outreach and program accomplishments.

- Responding to Media Inquiries/Working with the Press: As an outgrowth of providing service to the public, directors of programs should be prepared to respond to or address members of the local press when called upon, or when events make this necessary.

- The first step in good media relations is practicing quality treatment and responsibly operating medication assisted treatment (MAT) programs with consideration of community needs and concerns. This positions MAT providers to interact honestly and with confidence when addressing media inquiries.
• Opioid treatment programs (OTPs) operating within larger institutions should consult with institutional public affairs professionals who have local media contacts and can assist in preparing for media interviews or coverage.

• Appoint a media contact in the organization. Restrict the number of staff with authority to speak to the media on behalf of the organization. Educate other staff members on who is the official designee and main contact for media inquiries. Train the designated contacts on the proper response and organization protocol.

• Always respond in a timely manner to calls from the media. Go over the “ground rules” and deadlines with the reporter/journalist in advance of interviews or coverage.

• The job of a reporter is to get a story. Good reporters attempt to get all sides, but ultimately, the story and the deadline sometimes can impede the full presentation of fact and viewpoint. Be sure that responses are provided within agreed upon time frames.

• Be sensitive to journalist integrity and motives in producing a story or news item about or impacting the program. Know the journalist.

• Honest and credible responses to journalist/reporter inquiries about a treatment program are critical. Know the subject matter. Prepare for interviews by reviewing background information and facts.

• Know the most recent information about opioid addiction and medication-assisted treatment. Have fact sheets available.

• Keep responses to reporters and journalists simple and concise. Prepare your own “sound bites,” of five to ten seconds or less. Prepare and practice short, direct phrases to get your message across.

• During interviews, if you cannot answer a question, explain why, or inform the interviewer that you will research and provide response in a reasonable time, and do so. It is better to say why you cannot comment than to say “no comment.” This is particularly true on issues that may pertain to patient confidentiality.

• Be sensitive to leading questions that could be taken out of context. Clarify questions. Be as objective, positive, and flexible as possible in your response.

• Anticipate sensitive or surprising questions. Avoid negative or angry assertions. Do not challenge the credibility of the reporter, or that of other public figures, colleagues, or programs. Focus on your credibility and professional response.

• Update stories when facts change before the story is published or aired.

• If you give a reporter the name of another “expert,” be certain to notify that person that you have referred the reporter to him or her.
Media Outreach - Sample Press Release

[On letterhead of Organization - Name and Contact Information]

For Immediate Release

[City, State], Date

Contact: [Contact Person]

[Telephone and Fax Numbers]

Treatment Program Reports Positive Outcomes

The [Name of Program] has achieved positive treatment outcomes following the introduction, one year ago, of an expanded continuum of innovative medical services to its long-established medication assisted treatment program. [Name of Program Director or Medical Director] reports the findings in the program’s Annual Report. The report showed improvement in patient retention in treatment, continued decrease in use of heroin and other drugs, reduced incidence of infectious disease, and better use of medical services. The [name of program] has served as a major provider of addiction treatment for community members since [date].

“For more than three decades, studies have shown that medication assisted treatment with methadone medication is highly effective in improving the overall health of patients, greatly reducing heroin and other addictions, and significantly reducing the rate of HIV infection,” noted [name source of quote - Program Director or Medical Director]. “Previous studies indicated that 92.4% of methadone patients remained heroin free for over a 4.5-year period and 71% of those in treatment for over a 1-year period remained drug free.” The current program findings have yielded similar benefits of medication assisted treatment, and demonstrate that expanded on-site health assessments and on-site primary medical care at the program can significantly continue to improve patient outcomes.

The [name of program]’s Annual Report is available to the public. To receive a copy, and for information on the program’s medical and behavioral health services, call [telephone contact].

###

(This symbol, centered, denotes the end of the release)
Radio PSA Scripts

(30 Seconds)
If you know someone who is struggling with opiate addiction, know this: there is a place to turn for help. Your community offers medication assisted treatment programs using methadone and other pharmacotherapy medications, that can help individuals with opiate addiction and their families lead safe and productive lives. Talk to a counselor about a medication assisted treatment program and take the first step toward reclaiming your life. To find out about the medication assisted treatment programs your area, call [program telephone number]. That’s [program telephone number]. A public service of this station and [program name].

(30 Seconds)
Addiction knows no boundaries. Opiate addiction is a disease that affects all segments of our community. Medication assisted treatment programs that use methadone and other effective pharmacotherapies, give hope to men and women caught in the devastation of heroin addiction. Your community medication assisted treatment program can offer help to restore your health, self-respect, integrity, and well-being. If you are addicted to opiates, or know someone who is, do something about it. If you are 18 years or older, call [program name], your community medication assisted treatment provider, at [telephone number]. A public service of this station and [program name].

(15 Seconds)
If you know someone who is struggling with opiate addiction, know this: There are effective medical treatment programs in your community. Help them find the help they need. Call [name of program], your community medication assisted treatment provider, at [telephone number]. A public service of this station.

(15 Seconds)
Opiate addiction destroys lives. Methadone treatment programs can restore them. Let us help mend your life, your family, and community. Addiction knows no boundaries, it’s everybody’s business. Call [program name], your community medication assisted treatment provider, at [telephone number]. A public service of this station.
Voices of Methadone Patients

“I am an addict and now feel normal again. There is success in recovery.”

John Mihalega, Ohio

Raphael Agostini, New York - “Methadone has changed my life for the better because it keeps me out of trouble and off the streets.

I have better communication with my family and I understand and appreciate them so much more.”

Mark Beresky, Vermont - “As a teenager, something was missing in me. Heroin filled the emptiness that gnawed away at my life. It wasn’t long before I realized that it was destroying my life.

I tried every possible way to quit. Then I found methadone. Methadone treatment helped me rebuild my shattered life. My life was handed back to me because methadone treatment gave me the opportunity to try.

I now have a good job and feel that I am making my own family better and stronger.”

Barbara and Eddie Fernard, California - Barbara and Eddie Fernard met at a methadone treatment program and have been married for 15 years. They have seven children and one grandchild.

Since entering treatment, both have established full-time employment in property management. Barbara is currently enrolled in a paralegal course and Eddie works a second job to help pay for their children's three horses.

Both enjoy spending time with their family, and share the common goal of continuing to provide a drug-free and safe home environment for their children. They are currently saving to purchase a home of their own.

Helena Gilmore, New York - “Now that I am on a methadone program I can function normally. I don’t feel high or sick any more. I’ve been in the program for two years now.

I’m going to school and taking a course in computer technology.

I feel normal and that’s the best feeling of all.”

U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Treatment
www.samhsa.gov
Thelma Gonzalez, New York - “People can do anything when drug-free, stabilized on methadone, and involved in support groups and counseling. These are the most important steps towards recovery and independence.

Before entering the program, I didn’t know who I was. I was frustrated and emotionally exhausted. With the help, I have attained personal and professional goals.

I have obtained a lot of blessings, and give back to those in recovery. As a result of my overall growth, my self-esteem has increased. I am currently a child care worker and the president of the Patient’s Advisory Committee in my program.”

Debbie “D.J.” Jones, Arkansas - “I struggled with opiate addiction for over 20 years until I found methadone. My life was a mess. I just wanted to lead a normal life, but I couldn’t. I had no friends other than opiates until a caring doctor referred me to a methadone program.

Since then, I have been building my new life. I have a committed relationship with a loving partner, and we are buying our own home. I am back in school and plan to open my own computer repair and small network consultant business this year.

Today I have hopes and plans for a real future.”

Julia Lania, New York - “My husband, brother and oldest son were all heroin addicts and were shot dead in the streets. My youngest son was also a heroin addict for 20 years. He has been clean and sober for 14 months now.

I too am a former heroin addict and am in methadone treatment. I have been clean and sober for 12 years.

I now have a good job and live in peace. Yes, I have to work hard, but I know that I could not have made it alone. God bless methadone and the counselors who never gave up on me or my son.”

John Milhalega, Ohio - “One of the hardest and most fearful experiences of my life was telling my family I was in treatment for addiction and receiving methadone.

My recovery thus far has been successful and I pray that with all hope, it will continue to be so.

I am an addict and now feel normal again. There is success in recovery.”

Alice Randolph, Vermont - “I began using heroin at 15. In 1976, I found methadone. Everyone pressured me to get off it, because they saw methadone as just another drug.

When I moved to Vermont, my minister told me to stop beating myself up, and to think of myself as a diabetic on insulin. Then I really began to grow as a person. Without methadone I could not have developed my self-esteem and been able to love others and myself unconditionally. Mark and I have built a life for ourselves, and together, we continue to help people suffering from opiate addiction.”
Resources and References

Resources:

U.S. Department of Health and Human Services (HHS)

Substance Abuse and Mental Health Services Administration (SAMHSA)
301-443-8956, 301-443-1050 (fax)
www.samhsa.gov

SAMHSA's National Clearinghouse for Drug and Alcohol Information (NCADI)
1-800-729-6686, 301-468-6433 (fax)
www.ncadi.samhsa.gov

SAMHSA's National Treatment Referral Helpline
1-800-662-HELP, 1-800-487-4889 (TDD)

SAMHSA's National Treatment Locator
www.findtreatment.samhsa.gov

U.S. Department of Health and Human Services (HHS)

Substance Abuse and Mental Health Services Administration (SAMHSA)

Center for Substance Abuse Treatment (CSAT)
Division of Pharmacologic Therapies
301-443-7745, 301-480-3045 (fax)
www.samhsa.gov

The Patient Support and Community Education Project
www.samhsa.gov

Office of the Director, Consumer Affairs
301-443-5052, 301-443-7801 (fax)
www.samhsa.gov
U.S. Department of Health and Human Services (HHS)

Food and Drug Administration
Center for Drug Evaluation and Research
Narcotic Treatment Program Director
www.fda.gov/cder/compliance/ntpdir.pdf

National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
301-443-6460
www.nida.nih.gov

Executive Office of the President
Office of National Drug Control Policy
202-395-6700
www.whitehousedrugpolicy.gov

U.S. Department of Justice
U.S. Drug Enforcement Administration
Office of Diversion Control/Liaison Unit
202-307-7292 or 202-307-4875
www.usdoj.gov/dea

Other Resources:

American Association for the Treatment of Opioid Dependence
212-566-5555, 212-349-2944 (fax)
www.aatod.org

National Alliance of Methadone Advocates
212-595-6262
www.methadone.org

References:


Methadone, an opioid agonist medication, is recognized by the American Medical Association, which affirmed “the proven public health and patient health benefits of methadone maintenance and other similar opioid replacement programs in reducing the use of heroin.” This 1999 declaration followed a report from The Institute of Medicine (IOM) in 1995 and the conclusions of a 1997 National Institutes of Health (NIH) Consensus Development Panel. Both IOM and the NIH Consensus Panel recommended that opioid addiction be treated more like other medical conditions and that efforts be made to reform the methadone treatment system. To modernize the treatment system, the Secretary of the U.S. Department of Health and Human Services promulgated regulations that became effective May 18, 2001, to transfer oversight of opioid treatment programs from the Food and Drug Administration to the Substance Abuse and Mental Health Services Administration (SAMHSA). One of the key requirements of the regulations (42 CFR Part 8) is that opioid treatment programs become accredited, just like the process required for other mainstream health care facilities.

What does this requirement mean for patients, programs, and the community?

- Accreditation demands a higher standard of care for people receiving opiate agonist treatment for addiction to heroin and other opiates, by shifting responsibility for treatment decisions from regulators to clinicians.

- Accreditation allows for greater clinical discretion and medical judgment in determining appropriate individualized treatment, particularly in managing methadone/LAAM doses.

- Accreditation ensures that patients are appropriately assessed and matched to the right treatment, that treatment is individualized, and that the need for ongoing care is professionally assessed and monitored for quality.

- Accreditation provides patients and the community with assurance that quality treatment is being provided to those who are addicted to heroin and similar opioids.
• Accreditation's focus on quality of care integrates opiate agonist treatment into the mainstream of the nation's health care system and helps reduce the stigma associated with that treatment.

• Accreditation promotes state-of-the-art treatment services, with emphasis on outcome measures, especially those pertaining to reductions in crime and drug use, and engagement in productive employment. These changes enhance patient rights as well as outline patients' responsibilities.

Additionally, opioid treatment programs are regulated by the U.S. Department of Justice, Drug Enforcement Administration for their security and accounting of their medications, and by individual state authorities for compliance with state program standards.

1 Drugs that activate receptors in the brain are termed agonists. Agonists occupy receptors and switch them on. As a result, they produce an effect in the brain and body. Therefore, opioid agonists switch on one or more opioid receptors.


3 At proper doses, agonist therapy relieves the physiological craving for opioids, blocks the euphoric effects of opioids, and normalizes the physiology of the body impaired by opioid dependence.
<table>
<thead>
<tr>
<th>Topic</th>
<th>Heroin</th>
<th>Methadone</th>
<th>LAAM</th>
<th>Buprenorphine¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset of action</td>
<td>A few seconds</td>
<td>30 minutes</td>
<td>2 or more hours</td>
<td>30 to 40 minutes</td>
</tr>
<tr>
<td>Duration of action</td>
<td>4 to 6 hours</td>
<td>24 to 36 hours</td>
<td>48 to 72 hours</td>
<td>About 24-48 hours</td>
</tr>
<tr>
<td>Route of administration</td>
<td>Injection, snorting, smoking</td>
<td>Oral</td>
<td>Oral</td>
<td>Sublingual</td>
</tr>
<tr>
<td>Frequency of administration</td>
<td>Several times a day</td>
<td>Daily² or more frequently as needed</td>
<td>2-3 days per week</td>
<td>Every day or every other day</td>
</tr>
<tr>
<td>Effective dose</td>
<td>Ever increasing</td>
<td>Blocking dose¹, usually 80 to 120 mg</td>
<td>Blocking dose, 60 to 140 mg/day</td>
<td>2 to 32 mg⁴</td>
</tr>
<tr>
<td>Tolerance</td>
<td>Increasing tolerance</td>
<td>Tolerance is stable</td>
<td>Tolerance is stable</td>
<td>Tolerance is stable</td>
</tr>
<tr>
<td>Euphoric effects</td>
<td>Euphoria for up to 2 hours</td>
<td>No euphoria when stabilized</td>
<td>No euphoria when stabilized</td>
<td>No euphoria when stabilized</td>
</tr>
<tr>
<td>Overdose potential</td>
<td>High⁵ and increased</td>
<td>Rare⁶ -- Potential if mixed with other depressants</td>
<td>Rare⁶ -- Potential if mixed with other depressants</td>
<td>Very rare⁶</td>
</tr>
<tr>
<td>Overall safety</td>
<td>Potentially lethal</td>
<td>Very safe⁷ -- Possibly associated with rare cardiac irregularities -- Treatment choice in pregnancy</td>
<td>Overall good -- Associated with rare cardiac irregularities -- Not recommended for use in pregnancy or breast feeding</td>
<td>Overall good profile -- Suboxone injection will cause serious withdraw symptoms in dependent persons -- Not recommended for use in pregnancy or breast feeding -- Caution with liver disease -- Currently under study</td>
</tr>
</tbody>
</table>

¹ U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
² Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, www.samhsa.gov
³ Medication Assisted Treatment for the 21st Century
<table>
<thead>
<tr>
<th>Topic</th>
<th>Heroin</th>
<th>Methadone</th>
<th>LAAM</th>
<th>Buprenorphine¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Withdrawal</td>
<td>Within 3 or 4 hours after last dose</td>
<td>Within 24 to 36 hours after last dose</td>
<td>Within 48 to 72 hours after last dose</td>
<td>Within 36-48 hours after last dose</td>
</tr>
<tr>
<td>Craving</td>
<td>Recurring cravings</td>
<td>Eliminated with adequate dose</td>
<td>Eliminated with adequate dose</td>
<td>Craving may not be totally eliminated due to ceiling effect</td>
</tr>
<tr>
<td>Pregnancy and nursing</td>
<td>Heroin dependence poses grave risks for mother and fetus</td>
<td>Safe during pregnancy⁸</td>
<td>Not indicated</td>
<td>Not indicated, however study underway</td>
</tr>
<tr>
<td>Experience of pain and emotions</td>
<td>Blunted</td>
<td>Normal pain and full range of emotions</td>
<td>Normal pain and full range of emotions</td>
<td>Normal pain, but opioid analgesics may not be effective -- May need to switch to methadone -- Full range of emotions</td>
</tr>
<tr>
<td>Mood</td>
<td>Constant mood swings</td>
<td>Normal⁹</td>
<td>Normal⁹</td>
<td>Normal⁹</td>
</tr>
<tr>
<td>Physical reaction time and intellectual functioning</td>
<td>Impaired</td>
<td>Reaction time normal Intellectual functioning unimpaired on stable dose¹⁰</td>
<td>Reaction time presumed to be normal like methadone</td>
<td>Reaction time presumed to be normal like methadone. FDA cautions driving and operating heavy machinery in the beginning of treatment</td>
</tr>
<tr>
<td>HIV &amp; hepatitis C transmission</td>
<td>High rate with needle use and unprotected sex</td>
<td>Reduced/eliminated¹¹</td>
<td>Reduced/eliminated¹¹</td>
<td>Reduced/eliminated¹¹</td>
</tr>
<tr>
<td>Immune system for HIV positive persons</td>
<td>Rapid progression to AIDS</td>
<td>Progression slowed with methadone¹¹</td>
<td>Progression presumed same as methadone -- Data not available for LAAM</td>
<td>Progression presumed same as methadone -- Data not available for buprenorphine</td>
</tr>
<tr>
<td>Immune/endocrine system functioning</td>
<td>Impaired</td>
<td>Normalized during treatment¹²</td>
<td>Presumed normalized during treatment. Data not available</td>
<td>Presumed normalized during treatment. Data not available</td>
</tr>
<tr>
<td>Stress response</td>
<td>Suppressed</td>
<td>Normalized during treatment</td>
<td>Normalized during treatment</td>
<td>Normalized during treatment</td>
</tr>
</tbody>
</table>

²⁸
<table>
<thead>
<tr>
<th>Topic</th>
<th>Heroin</th>
<th>Methadone</th>
<th>LAAM</th>
<th>Buprenorphine¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Criminal activity</td>
<td>High level</td>
<td>Reduced/eliminated</td>
<td>Reduced/eliminated</td>
<td>Reduced/eliminated</td>
</tr>
<tr>
<td>Personal relationships</td>
<td>Disrupted</td>
<td>Potential for restoration,</td>
<td>Potential for restoration,</td>
<td>Potential for</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Improvement with counseling</td>
<td>Improvement with</td>
<td>restoration,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>counseling</td>
<td>Improvement</td>
</tr>
<tr>
<td>Employment</td>
<td>Deteriorating performance,</td>
<td>Full functioning</td>
<td>Full functioning</td>
<td>Full functioning¹³</td>
</tr>
<tr>
<td></td>
<td>loss of employment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Community impact</td>
<td>Destructive impact, high</td>
<td>Contributes to public</td>
<td>Contributes to public</td>
<td>Contributes to</td>
</tr>
<tr>
<td></td>
<td>crime, high death rate,</td>
<td>safety, low mortality, increased health</td>
<td>safety, low mortality,</td>
<td>public safety,</td>
</tr>
<tr>
<td></td>
<td>transmission of disease</td>
<td></td>
<td>increased health</td>
<td>low mortality,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>increased health</td>
</tr>
</tbody>
</table>

1. Two forms of buprenorphine: Subutex (pure buprenorphine) used for withdrawal and at treatment induction and Suboxone (buprenorphine with naloxone) used after initial treatment phase for longer-term maintenance to address addiction. Suboxone is recommended for all prescription and all out-of-clinic doses.
2. Rapid metabolizers and pregnant women may require dosing twice per day.
3. The dose at which heroin is ineffective and overdose potential practically eliminated.
4. The highest doses are equivalent to about 50# mg of methadone. A ceiling or limit exists for buprenorphine’s therapeutic effects.
5. Overdose potential is increased if mixed with other depressant drugs such as alcohol or benzodiazepines (anti-anxiety medications).
6. Overdose is rare with opioid-tolerant individuals in opioid treatment.
7. No serious side effects have been found in opioid-tolerant patients who have been in treatment for over 20 years. Long-term studies show no liver toxicity. Patients with hepatitis C and AIDS can be treated safely with methadone although changes in dose may be necessary.
8. Neonate who shows signs of withdrawal can be treated successfully with paragoric or tincture of opium. HIV-positive/AIDS mothers should not nurse. Mothers with hepatitis C can nurse with caution.
9. Mood remains normal if no other psychiatric or emotional conditions exist.
10. Methadone patients over the last 30 years have worked in all types of jobs and professions, including work with complicated machinery and computers, and professional work requiring advanced degrees.
11. In conjunction with proper education/counseling, these medications stop the use of heroin, but not injection of other drugs nor unsafe sexual practices.
12. Appears to improve immune response when compared to heroin.
13. FDA label warning cautions against heavy machinery use or driving during initial phase of treatment.
Fact Sheet: Opioid Use and Dependence: Medication Assisted Treatment

Opioid Use and Dependence — how widespread is it?

Heroin

• According to the Office of National Drug Control Policy, in the year 2000 there were more than 977,000 heroin dependent individuals in the United States. Drug Enforcement Administration data indicate that heroin is increasingly available at purer levels throughout the nation. The U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration’s (SAMHSA) 2001 National Household Survey on Drug Abuse reports that during the 1990s, heroin incidence rates rose to a level not reached since the 1970s. The survey shows that an estimated 146,000 persons used heroin for the first time in 2000.

• In 2001, for the first time since SAMHSA’s Drug Abuse Warning Network (DAWN) data have been collected, the number of mentions of narcotic analgesics in emergency departments (approximately 99,000) exceeded the number of heroin mentions (approximately 93,000). These data point to the fact that many prescription opioid drugs are now being abused by large numbers of people and are leading to a large number of emergency department admissions.

• In 2001, there were 638,484 emergency department visits related to drug abuse, or 252 visits per 100,000 population. Heroin accounted for 37 visits per 100,000 or 15 percent of the total emergency department visits nationwide. From 1994 to 2001, emergency department mentions regarding heroin increased 47 percent according to 2001 DAWN data.

• Heroin treatment admission rates between 1992 and 2000 increased by more than 100 percent in 18 states. In 1992, no state had a rate higher than 250 per 100,000 population; by 2000 seven states had surpassed that rate. According to the 2000 Treatment Episode Data Set (TEDS).

Prescription Opioids

• Evidence from around the country suggests that a significant percentage of patients in methadone programs are being treated for prescription opioid dependence. For example, Alaska estimates that there are 15,000 prescription opioid abusers in the state and that most methadone patients are not heroin-addicted individuals. One opioid treatment program in southwestern Virginia reported that 60 percent of the 290 people in outpatient treatment with methadone named OxyContin® as their primary drug of abuse. According to SAMHSA’s Center for Substance Abuse Treatment, in 2003, programs in Virginia and Kentucky reported that approximately 85 percent of admissions cite oxycodone as their primary drug of use. According to the 2001 DAWN data, from 1994 to 2001, emergency department mentions of narcotic analgesics and narcotic analgesic combinations were the most frequently mentioned in drug-related emergency department visits in 2001, constituting 9 percent of all emergency room mentions (99,317). Mentions of these narcotic analgesics and combinations rose 44 percent from 1999 to 2001 and 21 percent from 2000 to 2001. Significant long-term in-
creases in emergency department mentions of narcotic analgesics and combinations were found for hydrocodone and its combinations (up 131 percent since 1994), methadone (up 230 percent), morphine and its combinations (up 210 percent), oxycodone and its combinations (up 352 percent) and narcotic analgesics that were not specified (up 288 percent).

One year, from 2000 to 2001, methadone mentions increased by 37 percent and oxycodone and its combinations rose 70 percent. Unspecified narcotic analgesics rose 24 percent. Mentions of analgesics containing hydrocodone were statistically unchanged from 2000 to 2001, but were 41 percent higher than in 1999.

Opiate Use and Addiction – How is it treated?

A variety of treatments are available for heroin abuse and dependence:

- Long- or short-term residential treatment in a therapeutic community involving counseling in a highly structured residential environment.

- Outpatient programs emphasizing a range of behavioral counseling and psychotherapy.

- Medication assisted treatment that uses agonist or partial agonist medications (see chart at end of fact sheet for definition) such as methadone, LAAM, or buprenorphine to normalize brain chemistry, block the euphoric effects of opioids and relieve physiological cravings, and normalize body functions.

- Use of opioid antagonists (see chart at end of fact sheet for definition), such as naltrexone, to block the effects of opioid drugs; often used to prevent relapse to opioid use in highly selected populations.

While not considered formal treatment, self-help fellowships, such as Narcotics Anonymous and Methadone Anonymous, that utilize the "self-help" approach to abstinence can be used.

Methadone Treatment

Methadone treatment provides the patient who is opioid dependent with medication, health, social, and rehabilitation services that relieve withdrawal symptoms, reduce physiological cravings, and allow normalization of the body's functions. Methadone treatment has been available for over 30 years and has been confirmed effective for opioid dependence in numerous scientific studies.

Moreover, in 1997, the U.S. Department of Health and Human Services' National Institutes of Health (NIH) Consensus Panel found the following concerning methadone treatment: "Of the various treatments available, methadone maintenance treatment, combined with attention to medical, psychiatric and socioeconomic issues, as well as drug counseling, has the highest probability of being effective."

Methadone treatment programs are staffed by professionals with medical, clinical, and administrative expertise. Patients receive medication from a health professional. Patients routinely meet with a primary counselor (social worker, caseworker, or certified substance abuse counselor), attend clinic groups, and access medical and social services.

Methadone Is Not A Substitution of One Drug for Another

Methadone is not a substitute for opioids or any other short-acting opioid, and does not affect individuals in the same way. Methadone does not create a pleasurable or euphoric feeling; rather it relieves physiological opioid craving and is generally chosen by opioid-dependent individuals. Methadone normalizes the body's metabolic and hormonal functioning.
that were impaired by the use of heroin or other opioids. It is a corrective, not curative, treatment. Unlike the disruptive nature of short-acting chemicals on the brain, methadone has long-acting properties that provide metabolic stability. For example, methadone creates the physical stability that allows female menses to return to normal cycle after its disruption from heroin use. Methadone allows embryos and fetuses to develop in a safe and stable metabolic environment instead of experiencing withdrawal from heroin every six hours due to the mother's use.

Absence of Serious Adverse Effects

When taken as prescribed, long-term administration of methadone causes no adverse effects to the heart, lungs, liver, kidneys, blood, bones, brain, or other vital body organs. Some side effects may arise, such as constipation, water retention, drowsiness, skin rash, excessive sweating, and reported change in sexual drive. These may occur during the initial stages of treatment. These symptoms generally subside or disappear as methadone dosage is adjusted and stabilized, or when simple medical interventions are initiated. The myth that methadone rots the bones and teeth and is otherwise physically harmful has been shown to be scientifically unfounded. LAAM, a long-acting agonist medication, has been associated with cardiac irregularities.

Medication Interactions

Patients on methadone can be treated with most medications without serious interactions or contraindications. For example, patients with conditions such as hypertension, diabetes, pneumonia, cardiac conditions, cancers, psychiatric disorders, etc. may be treated effectively with routine regimens and medications. However, as with any medication, treatment program physicians must be aware of all other medications that their patients are taking. Coordination of methadone with certain other medications is necessary. For example, certain medications used to treat HIV/AIDS, epilepsy, tuberculosis, and hepatitis C may prompt the need for the program physician to change the methadone dose level. Medications such as dilantin for epilepsy and rifampin for tuberculosis increase the body's metabolism of methadone and, thus, prompt the need for an adjustment in the methadone dose or possibly splitting the dose to be taken twice daily instead of once. Therefore, it is very important that all physicians (primary care provider, surgeon, methadone treatment program physician, etc.) be aware of each other's involvement with the patient.

Use of Pain Medication with Methadone Patients

Methadone patients, at all dose levels, experience normal pain and, therefore, need analgesia following surgical procedures or any other painful medical or dental procedures. Pain management, which may also include medication, is required for chronic malignant and nonmalignant pain. Methadone maintenance treatment should be continued without lowering the maintenance dose. Opioids such as morphine, oxycodone, and pain-control analgesia (PCA) and even methadone itself can be used to treat methadone patients. However, because of their tolerance to opioids, methadone patients possibly will require higher doses of opioids and at more frequent intervals.

When prescribing methadone as a pain medication, the regular maintenance dose should be maintained and the methadone used for analgesia should be prescribed separately three to four times per day, since methadone's
analgesic properties last only from four to six hours. Methadone patients should not be prescribed medications for pain that contain opioid antagonists since the antagonists will precipitate withdrawal. According to the NIH Consensus Panel Report, methadone patients can be safely prescribed both opioid and non-opioid analgesics without antagonist properties.

**Methadone Treatment Truths**

**Cost-Effectiveness**

Methadone treatment is an effective contributor to the reduction of the economic and social burdens linked to opioid abuse. Most methadone-maintained patients are able to secure and maintain gainful employment, remain free of illicit or inappropriate use of opioids, improve health, and reduce the risk of exposure to HIV/AIDS.

Methadone treatment has positive outcomes for the individual and for the community. It has been found to be highly cost-effective. The Institute of Medicine in its 1995 report concluded that “methadone maintenance pays for itself on the day it is delivered, and post-treatment effects are an economic bonus.”

**Reduction in Heroin and Other Opioid Use**

Methadone treatment dramatically reduces opioid use after admission to methadone treatment and further declines as patients remain in treatment. SAMHSA's Services Research and Outcomes Study (SROST) validated these findings in 1998. The study found that “clients in methadone facilities composed the only group showing a significant decrease in heroin use (27 percent decline). Additional outcome follow-up from the California Drug and Alcohol Treatment Assessment (CALDATA), and the National Treatment Improvement Evaluation Study (NTIES) and Drug Abuse Treatment Outcome Study (DATOS), compiled by Gerstein and Johnson of the National Opinion Research Center (NORC) in 1999, found a 39 percent, 51 percent, and 69 percent reduction in heroin use respectively.

**Reduction in Criminality**

Methadone treatment is associated with reduced criminal activity. Decreases in criminal behavior are greater the longer a person is in treatment.

**Reduction in Risk of HIV/AIDS and Hepatitis**

The relationship between intravenous (IV) drug use, needle sharing, hepatitis, and HIV/AIDS exposure is well documented. Higher-dose methadone treatment (over 80 mgs.) is the most effective intervention for reducing the spread of HIV/AIDS and hepatitis, according to the Mount Sinai Journal of Medicine.

**Buprenorphine**

The Drug Addiction Treatment Act of 2000 (DATA 2000) permits physicians who are specially trained and meet specific qualifications to prescribe certain Food and Drug Administration (FDA) approved scheduled narcotic medications for the treatment of narcotic dependency. Buprenorphine is the first of these special narcotic medications to be approved by the FDA. DATA 2000 requires the physician to complete a special training course or hold a subspecialty board certification from either the American Board of Medical Specialties or the American Osteopathic Association, or certification from the American Society of Addiction Medicine. Additionally, DATA 2000 requires physicians to submit a notification for a waiver from the special registration requirements in the Controlled Substances Act for the provision of medication-assisted opioid therapy. This waiver allows qualifying physicians to practice medication-assisted opioid addiction therapy with specially FDA-approved narcotic medications for up to 30 patients.

Subutex® (buprenorphine hydrochloride) and Suboxone® (buprenorphine hydrochloride with naloxone hydrochloride) were approved by the Food and Drug Administration on October 8, 2002,
for the treatment of opioid dependence. These medications currently are being marketed as sublingual (SL) tablets. Buprenorphine medications will be available through specially trained physicians and opioid treatment programs for the treatment of opioid dependence. Research studies show this medication is similar to methadone in its ability to stabilize functioning so patients can participate in comprehensive treatment for their opioid dependence, according to Schottenfeld, R.S., et al.

In addition to drugs like heroin, addiction to prescription pain relievers like oxycodone, hydrocodone, and codeine are also treated with the new buprenorphine medications. Like methadone, buprenorphine suppresses withdrawal symptoms and blocks the effects of other opioids. A doctor who is qualified can determine if buprenorphine is an appropriate choice of treatment medications for a patient addicted to prescription pain relievers.

People can transfer from methadone to buprenorphine therapy, but because the two medications are different, patients need to be educated by their treatment provider or physician in the effects of, and differences between, agonist (methadone) and partial antagonist (buprenorphine) type drugs. A number of factors affect if buprenorphine is a good choice for someone who is currently in methadone treatment. It is also possible for patients on buprenorphine to be transferred to methadone therapy. Patients interested in learning more about the possibility of transferring therapies should discuss this with the doctor who is prescribing their medication.

The Food and Drug Administration’s New Drug Application Labeling states that patients who are methadone-maintained and are considering transferring to buprenorphine as a maintenance medication would need to be at a dose of 30 mgs. or less to make the transition safely. This is to reduce the interaction of the agonist medication (methadone) with the partial antagonist medication (buprenorphine). The likelihood of developing withdrawal symptoms during the transition increases proportionately with doses above 30 mgs. of methadone.

For additional information, please see the chart at the end of this fact sheet, call 1-800-BUP-CSAT, or visit the official Web site at www.buprenorphine.samhsa.gov

References


<table>
<thead>
<tr>
<th>Medication</th>
<th>Agonist</th>
<th>Partial Agonist</th>
<th>Antagonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone and LAAM</td>
<td>Buprenorphine and</td>
<td>Buprenorphine combined with Naloxone</td>
<td>Naltrexone</td>
</tr>
<tr>
<td></td>
<td>Buprenorphine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Action</td>
<td>Binds to opiate</td>
<td>Binds to the receptor* but produces minimal agonist</td>
<td>Binds to the receptor* and produces no activity, thus blocking the effect of agonists (i.e., morphine, endorphins).</td>
</tr>
<tr>
<td></td>
<td>receptor* and mimics</td>
<td>effects</td>
<td></td>
</tr>
<tr>
<td></td>
<td>the internal opiate</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Use</td>
<td>Methadone can be used</td>
<td>Buprenorphine alone for stabilization and medical</td>
<td>Maintenance</td>
</tr>
<tr>
<td></td>
<td>for maintenance and</td>
<td>withdrawal. Buprenorphine with Naloxone is used for</td>
<td></td>
</tr>
<tr>
<td></td>
<td>medical withdrawal.</td>
<td>maintenance.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LAAM is only for</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>maintenance.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Effective Dose</td>
<td>Methadone begins at</td>
<td>8-32 mgs daily or every other day sublingually dissolves</td>
<td>50 mgs daily oral and 150 mgs oral every other</td>
</tr>
<tr>
<td></td>
<td>80 mgs oral daily and</td>
<td>under the tongue in 3-7 minutes.</td>
<td>day.</td>
</tr>
<tr>
<td></td>
<td>LAAM begins at 60 mgs</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>oral every other day.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blockage</td>
<td>Starting at 80 mgs</td>
<td>Starting at 4 mgs</td>
<td>At any dose</td>
</tr>
<tr>
<td>Effect on Craving</td>
<td>Completely relieved</td>
<td>For some individuals the craving is completely relieved. Because of the ceiling effect that limits activity, some will experience craving and need full agonists treatment.</td>
<td>Does not relieve physiological craving and may induce secondary abstinence symptoms resulting in discomfort.</td>
</tr>
<tr>
<td>Medical Safety</td>
<td>Methadone over 80 mgs/day and LAAM over 60 mgs every other day is safe and prevents respiratory depression. Before starting LAAM, EKG is indicated. LAAM is associated with possible arrhythmia.</td>
<td>For opioid naive individuals, ceiling effect reduces possibility of respiratory depression.</td>
<td>Protects against respiratory depression. Some patients complain of discomfort and can cause inability to experience pleasure and other symptoms of the secondary abstinence syndrome.</td>
</tr>
<tr>
<td></td>
<td>Agonist</td>
<td>Partial Agonist</td>
<td>Antagonist</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td><strong>Withdrawal</strong></td>
<td>Methadone after 24 hours.</td>
<td>After 48 hours</td>
<td>None</td>
</tr>
<tr>
<td><strong>Severity of Withdrawal</strong></td>
<td>Methadone symptoms are milder but longer than heroin (7 days). LAAM is milder than methadone and longer.</td>
<td>Buprenorphine is milder than methadone but more protracted.</td>
<td>None</td>
</tr>
<tr>
<td><strong>Patient Acceptance, Retention in Treatment</strong></td>
<td>Good retention with patients in treatment up to 30 years without toxic effects.</td>
<td>Presumed to be good, but long-term data are not available.</td>
<td>Poor, patients leave early because of craving, secondary abstinence syndrome, and discomfort.</td>
</tr>
<tr>
<td><strong>Target Population</strong></td>
<td>All adults over 18 including pregnant women for methadone. LAAM is recommended for adults over 18 but not pregnant women.</td>
<td>Individuals age 16 and over with short histories of opioid dependence. Methadone patients on very low doses (i.e., 30 mgs and under). Not recommended for pregnant or nursing women.</td>
<td>Only a small group of opioid-dependent individuals respond. Non-responders should be transferred to agonist or partial agonist therapy.</td>
</tr>
<tr>
<td><strong>Pain Management</strong></td>
<td>Effectively treated with other opioids.</td>
<td>No analgesia; action is blocked, and if patient needs pain medication, must be transferred to methadone.</td>
<td>No analgesia; action is blocked, and if patient needs pain medication must be transferred to methadone.</td>
</tr>
<tr>
<td><strong>Pregnancy</strong></td>
<td>Methadone is recommended. LAAM is not recommended.</td>
<td>Under study</td>
<td>Contraindicated</td>
</tr>
<tr>
<td><strong>Breast Feeding</strong></td>
<td>Methadone is safe with HIV-negative and normal caution with HCV. LAAM is not recommended.</td>
<td>Under study</td>
<td>Contraindicated</td>
</tr>
</tbody>
</table>

*Receptor: Receptors are found throughout the body. However, in the brain, an opiate receptor is where internal opiates, such as endorphins, bind as well as the external opiates such as heroin, methadone, and buprenorphine. They can be thought of as a lock (i.e., the receptor) and key (i.e., the opiate). Methadone has the best fit as the key and most resembles the internal opiates in its action.*
Fact Sheet: Methadone Research Findings

History and Effectiveness of Methadone Maintenance Treatment

Methadone’s effectiveness, and the absence of any serious, long-term side effects from using it, have been demonstrated in numerous studies conducted over the past 30 years. Among the most commonly cited outcomes are:

- **Consumption of all illicit drugs declines** to less than 40 percent of pretreatment levels during the first year and eventually reaches 15 percent of pretreatment levels for patients who remain in treatment 2 years or more according to Ball and Ross, 1991; and Hubbard, et al, 1986.

- **Crime is reduced substantially**: For example, in the most detailed study of treatment outcomes to date, Ball and Ross, 1991, showed that during the first 4 months of treatment, crime decreased from 237 crime days per year per 100 addicted persons during an average year of their addiction to 69 crime days per year per 100 patients, a reduction of more than 70 percent (p. 205), declining further to only 14.5 crime days per year for patients in treatment 6 years or more.

- **Fewer individuals become infected with HIV**: A study by Metzger, et al, 1993, showed that over a 3-year period, 5 percent of patients in methadone treatment became HIV-positive (over and above those already positive at admission), while among a cohort of out-of-treatment addicts in the same neighborhood, 26 percent became HIV-positive (over and above those already positive at baseline).

- **Individual functioning improves**, as evidenced in improved family and other social relationships, increased employment, improved parenting, etc., according to the Substance Abuse and Mental Health Services Administrations, Center for Substance Abuse Treatment, 1994, and Lowinson, et al, 1992. For example, the 1992 Lowinson study of the first 15 years of methadone treatment documented employment rates of patients just below 60 percent. Even in the 1980s, when the economy weakened, crack use increased, and HIV infection rates increased dramatically, social productivity levels and employment remained at about 40 percent.

Methadone has been shown to be safe. It produces no serious or long-term side effects, and may improve immune system functioning in people who have experienced the deleterious effects of heroin addiction. Methadone’s clinical effectiveness has been documented in more than 300 published research studies, Hubbard, et al, 1986; Sells, et al, 1979. Furthermore, “comprehensive methadone maintenance, when combined with appropriate prenatal care, can reduce the incidence of obstetrical and fetal complications...and there is no reported evidence of any toxic effects of methadone in the woman, fetus, or child” according to the Institute of Medicine, 1995. Finally, at an annual average cost of $4,000/patient, methadone maintenance treatment is cost effective as stated in the *Federal Register*, 1999. The Treatment Outcome Prospective Study (TOPS), analyzed the average cost of treatment; rates of criminal activities; costs to society of various crimes; and economic benefits and costs. Using these data, Harwood, et al, 1988, found that for every $1 invested in treatment, $4 is recovered in social costs.
References


NOTICE

Reproduction Basis

☐ This document is covered by a signed "Reproduction Release (Blanket)" form (on file within the ERIC system), encompassing all or classes of documents from its source organization and, therefore, does not require a "Specific Document" Release form.

☒ This document is Federally-funded, or carries its own permission to reproduce, or is otherwise in the public domain and, therefore, may be reproduced by ERIC without a signed Reproduction Release form (either "Specific Document" or "Blanket").